Epigenetic Reprogramming and Re-differentiation of a Ewing Sarcoma Cell Line

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2015 Mar 26

PMID 25806369

Citations 17

Authors

Joseph B Moore 4th

David M Loeb

Kyung U Hong

Poul H Sorensen

Timothy J Triche

David W Lee

Michael I Barbato

Robert J Arceci

Affiliations

Soon will be listed here.

Abstract

Developmental reprogramming techniques have been used to generate induced pluripotent stem (iPS) cells from both normal and malignant cells. The derivation of iPS cells from cancer has the potential to provide a unique scientific tool to overcome challenges associated with the establishment of cell lines from primary patient samples and a readily expandable source of cells that may be used to model the initial disease. In the current study we developmentally reprogrammed a metastatic Ewing sarcoma (EWS) cell line to a meta-stable embryonic stem (ES)-like state sharing molecular and phenotypic features with previously established ES and iPS cell lines. EWS-iPS cells exhibited a pronounced drug resistant phenotype despite persistent expression of the oncogenic EWS-FLI1 fusion transcript. This included resistance to compounds that specifically target downstream effector pathways of EWS-FLI1, such as MAPK/ERK and PI3K/AKT, which play an important role in EWS pathogenesis. EWS-iPS cells displayed tumor initiation abilities in vivo and formed tumors exhibiting characteristic Ewing histopathology. In parallel, EWS-iPS cells re-differentiated in vitro recovered sensitivity to molecularly targeted chemotherapeutic agents, which reiterated pathophysiological features of the cells from which they were derived. These data suggest that EWS-iPS cells may provide an expandable disease model that could be used to investigate processes modulating oncogenesis, metastasis, and chemotherapeutic resistance in EWS.

Citing Articles

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.

Glaviano A, Foo A, Lam H, Yap K, Jacot W, Jones R Mol Cancer. 2023; 22(1):138.

PMID: 37596643 PMC: 10436543. DOI: 10.1186/s12943-023-01827-6.

An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool.

Javaid N, Choi S Stem Cells Int. 2022; 2022:4537335.

PMID: 36187228 PMC: 9522500. DOI: 10.1155/2022/4537335.

Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.

Becklin K, Draper G, Madden R, Kluesner M, Koga T, Huang M CRISPR J. 2022; 5(4):517-535.

PMID: 35972367 PMC: 9529369. DOI: 10.1089/crispr.2022.0032.

Modeling cancer progression using human pluripotent stem cell-derived cells and organoids.

Zhang M, Vandana J, Lacko L, Chen S Stem Cell Res. 2020; 49:102063.

PMID: 33137568 PMC: 7849931. DOI: 10.1016/j.scr.2020.102063.

IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.

Amin H, Morani A, Daw N, Lamhamedi-Cherradi S, Subbiah V, Menegaz B Cancers (Basel). 2020; 12(7).

PMID: 32630797 PMC: 7408058. DOI: 10.3390/cancers12071768.

References

McKinsey E, Parrish J, Irwin A, Niemeyer B, Kern H, Birks D . A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs. Oncogene. 2011; 30(49):4910-20. PMC: 4696862. DOI: 10.1038/onc.2011.197. View

Juergens H, Daw N, Geoerger B, Ferrari S, Villarroel M, Aerts I . Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011; 29(34):4534-40. PMC: 3236653. DOI: 10.1200/JCO.2010.33.0670. View

Chou B, Mali P, Huang X, Ye Z, Dowey S, Resar L . Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res. 2011; 21(3):518-29. PMC: 3193421. DOI: 10.1038/cr.2011.12. View

Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T . Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2007; 451(7175):141-6. DOI: 10.1038/nature06534. View

Hotta A, Cheung A, Farra N, Garcha K, Chang W, Pasceri P . EOS lentiviral vector selection system for human induced pluripotent stem cells. Nat Protoc. 2009; 4(12):1828-44. DOI: 10.1038/nprot.2009.201. View

May W, Grigoryan R, Keshelava N, Cabral D, Christensen L, Jenabi J . Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLoS One. 2013; 8(12):e80060. PMC: 3846563. DOI: 10.1371/journal.pone.0080060. View

Lessnick S, Ladanyi M . Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol. 2011; 7:145-59. PMC: 3555146. DOI: 10.1146/annurev-pathol-011110-130237. View

Arvand A, Denny C . Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene. 2001; 20(40):5747-54. DOI: 10.1038/sj.onc.1204598. View

Vormoor J, Baersch G, Decker S, Hotfilder M, Schafer K, Pelken L . Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice. Pediatr Res. 2001; 49(3):332-41. DOI: 10.1203/00006450-200103000-00006. View

10.

May W, Arvand A, Thompson A, Braun B, Wright M, Denny C . EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet. 1997; 17(4):495-7. DOI: 10.1038/ng1297-495. View

11.

Miser J, Goldsby R, Chen Z, Krailo M, Tarbell N, Link M . Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. Pediatr Blood Cancer. 2007; 49(7):894-900. DOI: 10.1002/pbc.21233. View

12.

Scotlandi K, Benini S, Nanni P, Lollini P, Nicoletti G, Landuzzi L . Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998; 58(18):4127-31. View

13.

Brown H, Unger C, Whitehouse A . Potential of herpesvirus saimiri-based vectors to reprogram a somatic Ewing's sarcoma family tumor cell line. J Virol. 2013; 87(12):7127-39. PMC: 3676103. DOI: 10.1128/JVI.03147-12. View

14.

Silvany R, Eliazer S, Wolff N, Ilaria Jr R . Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene. 2000; 19(39):4523-30. DOI: 10.1038/sj.onc.1203811. View

15.

Ziegler K, Bui T, Frisque R, Grandinetti A, Nerurkar V . A rapid in vitro polyomavirus DNA replication assay. J Virol Methods. 2004; 122(1):123-7. DOI: 10.1016/j.jviromet.2004.08.012. View

16.

Malempati S, Weigel B, Ingle A, Ahern C, Carroll J, Roberts C . Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2011; 30(3):256-62. PMC: 3269952. DOI: 10.1200/JCO.2011.37.4355. View

17.

Grier H, Krailo M, Tarbell N, Link M, Fryer C, Pritchard D . Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348(8):694-701. DOI: 10.1056/NEJMoa020890. View

18.

Erkizan H, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg J, Yuan L . A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009; 15(7):750-6. PMC: 2777681. DOI: 10.1038/nm.1983. View

19.

Rorie C, Thomas V, Chen P, Pierce H, OBryan J, Weissman B . The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 2004; 64(4):1266-77. DOI: 10.1158/0008-5472.can-03-3274. View

20.

Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F . Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A. 2009; 107(1):40-5. PMC: 2806714. DOI: 10.1073/pnas.0912407107. View